Stem definition | Drug id | CAS RN |
---|---|---|
antibiotics, cefalosporanic acid derivatives | 537 | 79350-37-1 |
Dose | Unit | Route |
---|---|---|
0.40 | g | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 4 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.10 mg/mL | Bocci G, Oprea TI, Benet LZ |
EoM (Fraction excreted unchanged in urine) | 41 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 29.33 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 47 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 0.24 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 1 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.31 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 3.20 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
April 28, 1989 | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug hypersensitivity | 54.10 | 17.87 | 83 | 4102 | 310604 | 63174233 |
Gastroenteritis staphylococcal | 43.35 | 17.87 | 7 | 4178 | 73 | 63484764 |
Secretion discharge | 32.64 | 17.87 | 16 | 4169 | 12215 | 63472622 |
Panic attack | 31.11 | 17.87 | 19 | 4166 | 22312 | 63462525 |
Clostridium difficile infection | 30.69 | 17.87 | 21 | 4164 | 29901 | 63454936 |
Pulmonary congestion | 29.99 | 17.87 | 17 | 4168 | 17401 | 63467436 |
Mucocutaneous candidiasis | 29.22 | 17.87 | 4 | 4181 | 11 | 63484826 |
Toxic epidermal necrolysis | 28.91 | 17.87 | 19 | 4166 | 25315 | 63459522 |
Biopsy colon abnormal | 27.51 | 17.87 | 5 | 4180 | 109 | 63484728 |
Dysbiosis | 26.41 | 17.87 | 7 | 4178 | 899 | 63483938 |
Gastrointestinal mucosa hyperaemia | 24.56 | 17.87 | 5 | 4180 | 201 | 63484636 |
Movement disorder | 24.12 | 17.87 | 16 | 4169 | 21645 | 63463192 |
Vaginal infection | 23.61 | 17.87 | 11 | 4174 | 7507 | 63477330 |
Foetal growth restriction | 23.56 | 17.87 | 11 | 4174 | 7542 | 63477295 |
Premature baby | 22.32 | 17.87 | 15 | 4170 | 20720 | 63464117 |
Oligohydramnios | 22.14 | 17.87 | 10 | 4175 | 6356 | 63478481 |
Stevens-Johnson syndrome | 22.07 | 17.87 | 16 | 4169 | 24934 | 63459903 |
Candida test positive | 21.79 | 17.87 | 6 | 4179 | 890 | 63483947 |
Malignant melanoma in situ | 21.56 | 17.87 | 6 | 4179 | 926 | 63483911 |
Pseudomembranous colitis | 21.52 | 17.87 | 8 | 4177 | 3104 | 63481733 |
Pulmonary mass | 21.16 | 17.87 | 15 | 4170 | 22581 | 63462256 |
Atypical mycobacterial pneumonia | 19.65 | 17.87 | 3 | 4182 | 21 | 63484816 |
Disorientation | 19.45 | 17.87 | 18 | 4167 | 39434 | 63445403 |
Neutropenia | 18.92 | 17.87 | 38 | 4147 | 174967 | 63309870 |
Vanishing bile duct syndrome | 18.26 | 17.87 | 5 | 4180 | 727 | 63484110 |
Circumoral oedema | 18.12 | 17.87 | 4 | 4181 | 238 | 63484599 |
Meniscus injury | 18.07 | 17.87 | 9 | 4176 | 7105 | 63477732 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Oral pustule | 42.57 | 22.73 | 8 | 2002 | 243 | 34954678 |
Psoriatic arthropathy | 30.16 | 22.73 | 17 | 1993 | 19781 | 34935140 |
Urticaria | 25.31 | 22.73 | 24 | 1986 | 62353 | 34892568 |
Tendon pain | 22.90 | 22.73 | 8 | 2002 | 2987 | 34951934 |
Acute generalised exanthematous pustulosis | 22.86 | 22.73 | 10 | 2000 | 6766 | 34948155 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Secretion discharge | 51.62 | 17.14 | 24 | 5692 | 14998 | 79723674 |
Panic attack | 48.89 | 17.14 | 27 | 5689 | 24189 | 79714483 |
Pulmonary congestion | 48.71 | 17.14 | 28 | 5688 | 27072 | 79711600 |
Oral pustule | 39.90 | 17.14 | 8 | 5708 | 273 | 79738399 |
Toxic epidermal necrolysis | 38.22 | 17.14 | 29 | 5687 | 44552 | 79694120 |
Movement disorder | 38.19 | 17.14 | 24 | 5692 | 27235 | 79711437 |
Drug hypersensitivity | 38.15 | 17.14 | 73 | 5643 | 298843 | 79439829 |
Pulmonary mass | 36.81 | 17.14 | 24 | 5692 | 29010 | 79709662 |
Clostridium difficile colitis | 34.49 | 17.14 | 24 | 5692 | 32259 | 79706413 |
Acute generalised exanthematous pustulosis | 34.17 | 17.14 | 19 | 5697 | 17235 | 79721437 |
Gastroenteritis staphylococcal | 33.34 | 17.14 | 7 | 5709 | 301 | 79738371 |
Psoriatic arthropathy | 31.24 | 17.14 | 33 | 5683 | 77966 | 79660706 |
Dysbiosis | 28.23 | 17.14 | 8 | 5708 | 1211 | 79737461 |
Stevens-Johnson syndrome | 28.22 | 17.14 | 23 | 5693 | 39143 | 79699529 |
Biopsy colon abnormal | 27.70 | 17.14 | 5 | 5711 | 96 | 79738576 |
Pseudomembranous colitis | 26.27 | 17.14 | 11 | 5705 | 5363 | 79733309 |
Agranulocytosis | 25.43 | 17.14 | 23 | 5693 | 45007 | 79693665 |
Vaginal infection | 25.31 | 17.14 | 11 | 5705 | 5869 | 79732803 |
Clostridium difficile infection | 22.54 | 17.14 | 21 | 5695 | 42664 | 79696008 |
Pneumonia mycoplasmal | 22.45 | 17.14 | 7 | 5709 | 1471 | 79737201 |
Mucocutaneous candidiasis | 21.35 | 17.14 | 4 | 5712 | 95 | 79738577 |
Clostridium test positive | 21.21 | 17.14 | 10 | 5706 | 6444 | 79732228 |
Urticaria | 20.89 | 17.14 | 43 | 5673 | 185158 | 79553514 |
Febrile neutropenia | 20.81 | 17.14 | 49 | 5667 | 230950 | 79507722 |
Drug reaction with eosinophilia and systemic symptoms | 20.26 | 17.14 | 24 | 5692 | 64220 | 79674452 |
Candida test positive | 20.04 | 17.14 | 6 | 5710 | 1100 | 79737572 |
Gastrointestinal mucosa hyperaemia | 19.88 | 17.14 | 5 | 5711 | 480 | 79738192 |
Neutropenia | 19.68 | 17.14 | 55 | 5661 | 287655 | 79451017 |
Tendon pain | 19.31 | 17.14 | 9 | 5707 | 5649 | 79733023 |
Food protein-induced enterocolitis syndrome | 17.72 | 17.14 | 3 | 5713 | 39 | 79738633 |
Pyrexia | 17.42 | 17.14 | 95 | 5621 | 678614 | 79060058 |
Carnitine deficiency | 17.19 | 17.14 | 4 | 5712 | 277 | 79738395 |
None
Source | Code | Description |
---|---|---|
ATC | J01DD08 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Third-generation cephalosporins |
ATC | J01RA15 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE COMBINATIONS OF ANTIBACTERIALS Combinations of antibacterials |
ATC | J01RA16 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE COMBINATIONS OF ANTIBACTERIALS Combinations of antibacterials |
CHEBI has role | CHEBI:36047 | antibacterial drugs |
CHEBI has role | CHEBI:88188 | allergenic drug |
MeSH PA | D000900 | Anti-Bacterial Agents |
MeSH PA | D000890 | Anti-Infective Agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Acute otitis media | indication | 3110003 | |
Gonorrhea | indication | 15628003 | DOID:7551 |
Haemophilus Influenzae Acute Otitis Media | indication | 19021002 | |
Acute gonococcal cervicitis | indication | 20943002 | DOID:10615 |
Acute gonococcal urethritis | indication | 29864006 | |
Bronchitis | indication | 32398004 | DOID:6132 |
Streptococcal tonsillitis | indication | 41582007 | |
Upper respiratory infection | indication | 54150009 | |
Urinary tract infectious disease | indication | 68566005 | |
Tonsillitis | indication | 90176007 | DOID:10456 |
Acute bacterial bronchitis | indication | 233598009 | |
Escherichia coli urinary tract infection | indication | 301011002 | |
Proteus urinary tract infection | indication | 301012009 | |
Streptococcus pyogenes infection | indication | 302809008 | |
Infective otitis media | indication | 312218008 | |
Pharyngitis | indication | 405737000 | DOID:2275 |
Acute exacerbation of chronic bronchitis | indication | 425748003 | |
Moraxella Catarrhalis Acute Otitis Media | indication | 703469002 | |
Haemophilus Influenzae Bronchitis | indication | ||
Haemophilus Influenzae Chronic Bronchitis | indication | ||
Streptococcus Pneumoniae Chronic Bronchitis | indication | ||
Streptococcus Pneumoniae Bronchitis | indication | ||
Pneumonia due to Escherichia coli | off-label use | 51530003 | |
Acute bacterial sinusitis | off-label use | 75498004 | |
Haemophilus Parahaemolyticus Pneumonia | off-label use | ||
Haemophilus Parainfluenzae Pneumonia | off-label use | ||
Impaired renal function disorder | contraindication | 197663003 | |
Pseudomembranous enterocolitis | contraindication | 397683000 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 2.45 | acidic |
pKa2 | 2.54 | acidic |
pKa3 | 3.24 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
500MG/5ML | SUPRAX | LUPIN LTD | N202091 | Feb. 20, 2013 | RX | FOR SUSPENSION | ORAL | 9233112 | Dec. 14, 2028 | METHODS FOR TREATING BACTERIAL INFECTIONS |
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
D(2) dopamine receptor | GPCR | IC50 | 4.24 | WOMBAT-PK | |||||
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | Enzyme | IC50 | 5.92 | CHEMBL | |||||
Bacterial penicillin-binding protein | Enzyme | INHIBITOR | CHEMBL | CHEMBL | |||||
Streptokinase A | Enzyme | EC50 | 7.22 | WOMBAT-PK |
ID | Source |
---|---|
4019391 | VUID |
N0000147544 | NUI |
D00258 | KEGG_DRUG |
25033 | RXNORM |
C0060400 | UMLSCUI |
CHEBI:472657 | CHEBI |
C04 | PDB_CHEM_ID |
CHEMBL1541 | ChEMBL_ID |
D020682 | MESH_DESCRIPTOR_UI |
DB00671 | DRUGBANK_ID |
10898 | IUPHAR_LIGAND_ID |
97I1C92E55 | UNII |
5362065 | PUBCHEM_CID |
233747 | MMSL |
4374 | MMSL |
d00072 | MMSL |
387536009 | SNOMEDCT_US |
96052006 | SNOMEDCT_US |
4019391 | VANDF |
125110-14-7 | SECONDARY_CAS_RN |
002737 | NDDF |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Cefixime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-766 | POWDER, FOR SUSPENSION | 100 mg | ORAL | ANDA | 27 sections |
Cefixime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-766 | POWDER, FOR SUSPENSION | 100 mg | ORAL | ANDA | 27 sections |
Cefixime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-767 | POWDER, FOR SUSPENSION | 200 mg | ORAL | ANDA | 27 sections |
Cefixime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-767 | POWDER, FOR SUSPENSION | 200 mg | ORAL | ANDA | 27 sections |
SUPRAX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 27437-201 | TABLET | 400 mg | ORAL | ANDA | 27 sections |
SUPRAX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 27437-203 | TABLET, CHEWABLE | 100 mg | ORAL | ANDA | 19 sections |
SUPRAX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 27437-203 | TABLET, CHEWABLE | 100 mg | ORAL | ANDA | 19 sections |
SUPRAX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 27437-205 | TABLET, CHEWABLE | 200 mg | ORAL | ANDA | 19 sections |
SUPRAX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 27437-205 | TABLET, CHEWABLE | 200 mg | ORAL | ANDA | 19 sections |
SUPRAX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 27437-206 | POWDER, FOR SUSPENSION | 200 mg | ORAL | ANDA | 27 sections |
SUPRAX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 27437-207 | POWDER, FOR SUSPENSION | 500 mg | ORAL | NDA | 27 sections |
SUPRAX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 27437-208 | CAPSULE | 400 mg | ORAL | NDA | 27 sections |
Cefixime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-673 | POWDER, FOR SUSPENSION | 100 mg | ORAL | ANDA | 22 sections |
Cefixime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-673 | POWDER, FOR SUSPENSION | 100 mg | ORAL | ANDA | 22 sections |
Cefixime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-674 | POWDER, FOR SUSPENSION | 200 mg | ORAL | ANDA | 22 sections |
Cefixime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-674 | POWDER, FOR SUSPENSION | 200 mg | ORAL | ANDA | 22 sections |
SUPRAX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54348-797 | CAPSULE | 400 mg | ORAL | ANDA | 27 sections |
SUPRAX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54348-797 | CAPSULE | 400 mg | ORAL | ANDA | 27 sections |
Cefixime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62250-663 | POWDER, FOR SUSPENSION | 100 mg | ORAL | ANDA | 27 sections |
Cefixime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62250-663 | POWDER, FOR SUSPENSION | 100 mg | ORAL | ANDA | 27 sections |
Cefixime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62250-664 | POWDER, FOR SUSPENSION | 200 mg | ORAL | ANDA | 27 sections |
Cefixime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62250-664 | POWDER, FOR SUSPENSION | 200 mg | ORAL | ANDA | 27 sections |
Cefixime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62250-668 | POWDER, FOR SUSPENSION | 500 mg | ORAL | ANDA | 27 sections |
Cefixime | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62250-668 | POWDER, FOR SUSPENSION | 500 mg | ORAL | ANDA | 27 sections |
Cefixime | Human Prescription Drug Label | 1 | 65862-751 | POWDER, FOR SUSPENSION | 100 mg | ORAL | ANDA | 25 sections |
Cefixime | Human Prescription Drug Label | 1 | 65862-752 | POWDER, FOR SUSPENSION | 200 mg | ORAL | ANDA | 25 sections |
CEFIXIME | Human Prescription Drug Label | 1 | 67877-584 | CAPSULE | 400 mg | ORAL | ANDA | 24 sections |
CEFIXIME | Human Prescription Drug Label | 1 | 67877-584 | CAPSULE | 400 mg | ORAL | ANDA | 24 sections |
SUPRAX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68180-202 | POWDER, FOR SUSPENSION | 100 mg | ORAL | ANDA | 27 sections |
SUPRAX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68180-202 | POWDER, FOR SUSPENSION | 100 mg | ORAL | ANDA | 27 sections |